Bionano Genomics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Bionano Genomics

10/08/2026 22:46

Bionano Genomics, Inc. BNGO.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.99.  The mean expectation of two analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -70 cents to -67 cents per share.
Revenue rose 21.4% to $8.17 million from a year ago; analysts expected $7.48 million. 
Bionano Genomics, Inc.'s reported EPS for the quarter was a loss of 64 cents​.
The company reported a quarterly loss of $7.42 million.
Bionano Genomics, Inc. shares had risen by 2.7% this quarter and lost 24.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 13.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about 76.8% above its last closing price of $1.16
This summary was machine generated from LSEG data August 10 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.68
-0.64
Beat
Mar. 31 2026 
-0.88
-0.76
Beat
Dec. 31 2025 
-1.40
-0.03
Beat
Sep. 30 2025 
-1.91
-1.59
Beat